Past exam of the biochemistry course of the University of Cambridge / 2025 / Paper 3 / Section I

Genome management helps explain the architecture of the eukaryotic cell cycle, but it does not establish a single historical cause for its origin. Larger genomes, multiple chromosomes, chromatin and compartmentalisation create problems of complete copying and accurate allocation. The cell cycle solves these problems while also coordinating growth, environmental responses and reproduction. A functional explanation of a modern mechanism must therefore be distinguished from a reconstruction of why that mechanism first evolved.

The basic requirement predates eukaryotes: a reproducing biological cell must copy inherited information and distribute sufficient copies to its offspring. Bacteria also regulate initiation, resolve intertwined DNA and coordinate chromosome segregation with division. The relevant evolutionary change is not the invention of any copying–division cycle from nothing, but the origin and elaboration of particular eukaryotic solutions. Conversely, a large genome need not encode a proportionately larger number of functions: repetitive and other non-coding DNA can expand without a matching increase in regulatory complexity.

In a typical proliferating eukaryotic biological cell, S phase duplicates nuclear DNA and M phase distributes the copies through mitosis and cytokinesis. Separating these processes permits a clear sequence: establish competent replication machinery, replicate, finish and repair, segregate, then separate daughters. G1 phase and G2 phase provide opportunities to integrate growth and environmental information. Their duration and even their conspicuous presence vary: early embryonic cycles can alternate rapidly between S phase and M phase, whereas other biological cells stop dividing or undertake endoreduplication. Thus the familiar four-phase diagram is one regulated implementation, not a universal definition of all possible eukaryotic reproduction.

A larger genome places an immediate demand on replication capacity. In an idealised model, $N$ simultaneously active bidirectional origin of replication sites, each producing two replication forks moving at speed $v$, copy a DNA amount $G$ in time $T$ only ifHere $v$ is measured in base pairs per unit time and $G$ in base pairs; both sides have the same units. Evenly distributed origins with synchronous firing and no interruptions make the bound attainable in the ideal model. Real S phase includes asynchronous firing, unequal origin spacing and replication fork delays, so the inequality is a capacity requirement rather than a reliable prediction of completion time. Increasing origin number solves a throughput problem but creates a control problem: each region must be copied once, with gaps filled and rereplication prevented.

replication origin licensing separates permission from execution. When cyclin-dependent kinase activity is low, the origin recognition complex, Cdc6 and Cdt1 load inactive MCM2-7 double hexamers onto DNA. Later kinase activity permits firing while blocking renewed licensing. Reconstitution with purified budding-yeast components showed ATP-dependent loading of head-to-head MCM2-7 complexes; structural and biochemical assays distinguished loaded DNA helicase precursors from active unwinding machinery.^[ref] An explicit separation between licensing and firing makes parallel replication compatible with a once-per-cycle constraint.

Physical complexity also matters. Multiple sister chromatids must remain paired after copying, acquire suitable spindle attachments and then separate together. Cohesin maintains their association; kinetochores connect chromosomes to the spindle apparatus; regulated separase activation removes cohesion. chromosome condensation and DNA topoisomerases help manage the long, interlinked polymers. The spindle checkpoint delays anaphase while attachment is incomplete, rather than relying on a fixed waiting time. Additional DNA damage checkpoints and the replication checkpoint coordinate entry into division with the state of the template and replication machinery. These mechanisms can buffer errors whose costs grow with the number of essential elements that must be inherited, although none guarantees perfect fidelity.

A shared biochemical controller ties these tasks together. Rising cyclin-dependent kinase activity favours replication and then mitotic events, while regulated ubiquitin-dependent destruction of cyclins and other substrates creates directionality and resets the system. In fission yeast, an engineered single cyclin–kinase module could support ordered progression using activity thresholds despite removal of much canonical regulation. This demonstrates that a relatively small control core can organise complex downstream events; it does not demonstrate that the engineered strain reconstructs an ancestral eukaryote.^[ref]

The hypothesis also has limits. cell growth, nutrient availability and allocation of organelles would still need coordination even for a smaller genome. Multicellular organisms add requirements for developmental signals and restraint of inappropriate cell proliferation. Closed mitosis in some organisms shows that nuclear-envelope breakdown is not an obligatory solution; ongoing organelle replication also need not follow the nuclear programme exactly. Moreover, regulation can become more elaborate without a proportional increase in genome size. Present-day correlations cannot decide which trait evolved first.

Testing the historical claim would require comparative analysis of regulatory components across diverse eukaryotes and relevant outgroups, reconstruction of gene gains and losses, and experiments that alter replication burden independently of biological cell size and growth rate. For example, increasing origin spacing while holding DNA content fixed tests replication completion, whereas adding dispensable DNA with compensatory origins tests increased genome size more specifically. Measure completion, segregation errors, genotype fitness and stress responses; an engineered defect under laboratory conditions cannot by itself reveal ancient selection pressures. The defensible conclusion is that genome size and physical organisation supplied important demands that cell-cycle regulation meets, while the evolutionary origin of that regulation remains a broader, multicausal question.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.